FDA grants priority review to Roche’s Mabthera/Rituxan (rituximab)
Roche announced the FDA has accepted the company’s sBLA and granted Priority Review for the use of MabThera®/Rituxan® (rituximab), in combination with glucocorticoids, for treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older. June 12, 2019